0001209191-21-016973.txt : 20210303
0001209191-21-016973.hdr.sgml : 20210303
20210303170132
ACCESSION NUMBER: 0001209191-21-016973
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210302
FILED AS OF DATE: 20210303
DATE AS OF CHANGE: 20210303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McFarlane Neil F.
CENTRAL INDEX KEY: 0001681098
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36399
FILM NUMBER: 21710126
MAIL ADDRESS:
STREET 1: C/O RETROPHIN, INC.
STREET 2: 12255 EL CAMINO REAL, SUITE 250
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adamas Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001328143
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 421560076
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1900 POWELL ST., SUITE 1000
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: 510-450-3554
MAIL ADDRESS:
STREET 1: 1900 POWELL ST., SUITE 1000
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
FORMER COMPANY:
FORMER CONFORMED NAME: NeuroMolecular Pharmaceuticals Inc
DATE OF NAME CHANGE: 20050524
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-02
0
0001328143
Adamas Pharmaceuticals Inc
ADMS
0001681098
McFarlane Neil F.
C/O ADAMAS PHARMACEUTICALS, INC.
1900 POWELL ST., SUITE 1000
EMERYVILLE
CA
94608
0
1
0
0
Chief Executive Officer
Common Stock
2021-03-02
4
A
0
300000
0.00
A
525000
D
The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 1/3rd of the total number of Restricted Stock Units will vest on each of March 1, 2022, March 1, 2023 and March 1, 2024, subject to Reporting Person's Continuous Service as of each such date.
/s/ Christopher B. Prentiss, Attorney-in-fact
2021-03-03